Which prostate cancer drug is easier on patients? new trial aims to find out

NCT ID NCT06173362

Recruiting now Symptom relief Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial compares the side effects of two standard treatments for advanced prostate cancer: abiraterone plus prednisone versus darolutamide alone. Researchers will track how many patients experience severe side effects (grade 3 or higher) over the course of treatment. The goal is to help doctors and patients choose the option with fewer serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abiraterone, prednisone, and darolutamide
What this could lead to: If successful, this study could help doctors choose the drug with fewer severe side effects for advanced prostate cancer patients.
What could go wrong: This is a small, early-phase trial (75 people) focused on side effects, not on curing cancer. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE ADENOCARCINOMA STAGE III PROSTATE CANCER AJCC V8 STAGE IV PROSTATE CANCER AJCC V8

Contacts and locations

Show contact details

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.